Skip to main content

Emtricitabine / tenofovir Alafenamide News

2014 to 2021 Saw Increase in HIV Testing, PrEP in Transgender Persons

MONDAY, Dec. 18, 2023 – From 2014 to 2021, there was an increase in the number of transgender persons with an HIV test and who received preexposure prophylaxis (PrEP), according to a study published...

FDA Approves Descovy (emtricitabine and tenofovir alafenamide) for HIV Pre-Exposure Prophylaxis (PrEP)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 3, 2019-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a pre-exposure prophylaxis (PrEP) in...

FDA Approves Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) for Treatment of HIV-1 Infection

FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 7, 2018-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy (bictegravir...

FDA Approves Descovy (emtricitabine and tenofovir alafenamide), Gilead’s Third TAF-Based HIV Therapy

FOSTER CITY, Calif., April 04, 2016 --(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Descovy® (emtricitabine 200 ...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Pre-Exposure Prophylaxis, HIV Infection

Emtricitabine / tenofovir Alafenamide patient information at Drugs.com